LOX-1 as a biological marker and therapeutic target in cardiovascular pathology (literature review)

Cover Page

Cite item

Full Text

Abstract

Cardiovascular diseases (CVD) are a global medical, social and economic problem. Currently, the search and study of new biological markers that can provide early diagnosis of CVD, serve as a laboratory tool for evaluating the effectiveness of treatment or be used as prognostic markers and criteria for risk stratification continues. The interest of scientists is focused on the study of the type 1 lectin-like receptor for oxidized low-density lipoproteins (LOX-1) as a diagnostic and prognostic marker in CVD. The presented literature review highlights the potential significance of the LOX-1 study as a diagnostic and prognostic laboratory tool in CVD. It is expected that future clinical and experimental studies will confirm the possibility of using LOX-1 as an additional non-invasive tool for diagnosis and prognosis assessment in patients with CVD. Modulation of LOX-1 levels and expression using pharmacological drugs may prove to be a promising direction for the treatment of CVD.

About the authors

Amina M. Alieva

Pirogov Russian National Research Medical University

Author for correspondence.
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0001-5416-8579
SPIN-code: 2749-6427

Cand. Sci. (Med.)

Russian Federation, Moscow

Irina E. Baykova

Pirogov Russian National Research Medical University

Email: 1498553@mail.ru
ORCID iD: 0000-0003-0886-6290
SPIN-code: 3054-8884

Cand. Sci. (Med.)

Russian Federation, Moscow

Elena V. Reznik

Pirogov Russian National Research Medical University

Email: elenaresnik@gmail.com
ORCID iD: 0000-0001-7479-418X
SPIN-code: 3494-9080

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Natalia V. Teplova

Pirogov Russian National Research Medical University

Email: teplova.nv@yandex.ru
ORCID iD: 0000-0002-7181-4680
SPIN-code: 9056-1948

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Ramiz K. Valiev

Loginov Moscow Clinical Scientific Center

Email: radiosurgery@bk.ru
ORCID iD: 0000-0003-1613-3716
SPIN-code: 2855-2867

Cand. Sci. (Med.)

Russian Federation, Moscow

Malika Kh. Gyzyeva

Pyatigorsk Medical and Pharmaceutical Institute – a branch of the Volgograd State Medical University

Email: amisha_alieva@mail.ru
ORCID iD: 0009-0008-9105-1191

Student

Russian Federation, Pyatigorsk

Albina B. Sultangalieva

Pirogov Russian National Research Medical University

Email: albina_sult_2002@mail.ru
ORCID iD: 0009-0008-4194-8486

Student

Russian Federation, Moscow

Irina A. Kotikova

Pirogov Russian National Research Medical University

Email: kotikova.ia@mail.ru
ORCID iD: 0000-0001-5352-8499
SPIN-code: 1423-7300

Student

Russian Federation, Moscow

Natalia A. Novikova

Petrovsky National Research Centre of Surgery

Email: amisha_alieva@mail.ru
ORCID iD: 0000-0002-3639-270X

Cand. Sci. (Med.)

Russian Federation, Moscow

Sergey A. Korvyakov

Petrovsky National Research Centre of Surgery

Email: amisha_alieva@mail.ru
ORCID iD: 0000-0002-0237-524X

Cand. Sci. (Med.)

Russian Federation, Moscow

Igor G. Nikitin

Pirogov Russian National Research Medical University

Email: igor.nikitin.64@mail.ru
ORCID iD: 0000-0003-1699-0881

D. Sci. (Med.), Prof.

Russian Federation, Moscow

References

  1. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010
  2. Deng P, Fu Y, Chen M, et al. Temporal trends in inequalities of the burden of cardiovascular disease across 186 countries and territories. Int J Equity Health. 2023;22(1):164. doi: 10.1186/s12939-023-01988-2
  3. Silva S, Fatumo S, Nitsch D. Mendelian randomization studies on coronary artery disease: a systematic review and meta-analysis. Syst Rev. 2024;13(1):29. doi: 10.1186/s13643-023-02442-8
  4. Алиева А.М., Теплова Н.В., Батов М.А., и др. Пентраксин-3 – перспективный биологический маркер при сердечной недостаточности: литературный обзор. Consilium Medicum. 2022;24(1):53-9 [Alieva AM, Teplova NV, Batov MA, et al. Pentraxin-3 – a promising biological marker in heart failure: literature review. Consilium Medicum. 2022;24(1):53-9 (in Russian)]. doi: 10.26442/20751753.2022.1.201382
  5. Алиева А.М., Резник Е.В., Пинчук Т.В., и др. Фактор дифференцировки роста-15 (GDF-15) как биологический маркер при сердечной недостаточности. Архивъ внутренней медицины. 2023;13(1):14-23 [Alieva AM, Reznik EV, Pinchuk TV, et al. Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure. The Russian Archives of Internal Medicine. 2023;13(1):14-23 (in Russian)]. doi: 10.20514/2226-6704-2023-13-1-14-23
  6. Алиева А.М., Теплова Н.В., Кисляков В.А., и др. Биомаркеры в кардиологии: микроРНК и сердечная недостаточность. Терапия. 2022;1:60-70 [Alieva AM, Teplova NV, Kislyakov VA, et al. Biomarkery v kardiologii: mikroRNK i serdechnaya nedostatochnost'. Terapiya. 2022;1:60-70 (in Russian)]. doi: 10.18565/therapy.2022.1.60-70
  7. Lubrano V, Balzan S, Papa A. LOX-1 variants modulate the severity of cardiovascular disease: state of the art and future directions. Mol Cell Biochem. Epub 2023 Oct 3. doi: 10.1007/s11010-023-04859-0
  8. Sánchez-León ME, Loaeza-Reyes KJ, Matias-Cervantes CA, et al. LOX-1 in Cardiovascular Disease: A Comprehensive Molecular and Clinical Review. Int J Mol Sci. 2024;25(10):5276. doi: 10.3390/ijms25105276
  9. Bagheri B, Khatibiyan Feyzabadi Z, Nouri A, et al. Atherosclerosis and Toll-Like Receptor4 (TLR4), Lectin-Like Oxidized Low-Density Lipoprotein-1 (LOX-1), and Proprotein Convertase Subtilisin/Kexin Type9 (PCSK9). Mediators Inflamm. 2024;2024:5830491. doi: 10.1155/2024/5830491
  10. Truthe S, Klassert TE, Schmelz S, et al. Role of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Inflammation and Pathogen-Associated Interactions. J Innate Immun. 2024;16(1):105-32. doi: 10.1159/000535793
  11. Pyrpyris N, Dimitriadis K, Beneki E, et al. LOX-1 Receptor: A Diagnostic Tool and Therapeutic Target in Atherogenesis. Curr Probl Cardiol. 2024;49(1 Pt. C):102117. doi: 10.1016/j.cpcardiol.2023.102117
  12. Munno M, Mallia A, Greco A, et al. Radical Oxygen Species, Oxidized Low-Density Lipoproteins, and Lectin-like Oxidized Low-Density Lipoprotein Receptor 1: A Vicious Circle in Atherosclerotic Process. Antioxidants (Basel). 2024;13(5):583. doi: 10.3390/antiox13050583
  13. Barreto J, Karathanasis SK, Remaley A, et al. Role of LOX-1 (Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1) as a Cardiovascular Risk Predictor: Mechanistic Insight and Potential Clinical Use. Arterioscler Thromb Vasc Biol. 2021;41(1):153-66. doi: 10.1161/ATVBAHA.120.315421
  14. Inoue N, Okamura T, Kokubo Y, et al. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem. 2010;56(4):550-8. doi: 10.1373/clinchem.2009.140707
  15. Markstad H, Edsfeldt A, Yao Mattison I, et al. High Levels of Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 Are Associated With Carotid Plaque Inflammation and Increased Risk of Ischemic Stroke. J Am Heart Assoc. 2019;8(4):e009874. doi: 10.1161/JAHA.118.009874
  16. Skarpengland T, Skjelland M, Kong XY, et al. Increased Levels of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Ischemic Stroke and Transient Ischemic Attack. J Am Heart Assoc. 2018;7(2):e006479. doi: 10.1161/JAHA.117.006479
  17. Otsuki T, Maeda S, Mukai J, et al. Association between plasma sLOX-1 concentration and arterial stiffness in middle-aged and older individuals. J Clin Biochem Nutr. 2015;57(2):151-5. doi: 10.3164/jcbn.15-27
  18. Zhang Q, Chu Y, Jin G, et al. Association Between LOX-1, LAL, and ACAT1 Gene Single Nucleotide Polymorphisms and Carotid Plaque in a Northern Chinese Population. Genet Test Mol Biomarkers. 2020;24(3):138-44. doi: 10.1089/gtmb.2019.0209
  19. Salehipour P, Rezagholizadeh F, Mahdiannasser M, et al. Association of OLR1 gene polymorphisms with the risk of coronary artery disease: A systematic review and meta-analysis. Heart Lung. 2021;50(2):334-43. doi: 10.1016/j.hrtlng.2021.01.015
  20. Xu X, Hou X, Liang Y, et al. The gene polymorphism of LOX1 predicts the incidence of LVH in patients with essential hypertension. Cell Physiol Biochem. 2014;33(1):88-96. doi: 10.1159/000356652
  21. Sheikh MSA. Circulatory soluble LOX-1 is a novel predictor for coronary artery disease patients. Cardiovasc J Afr. 2023;34(2):104-8. doi: 10.5830/CVJA-2022-038
  22. Md Sayed AS, Zhao Z, Guo L, et al. Serum lectin-like oxidized-low density lipoprotein receptor-1 and adiponectin levels are associated with coronary artery disease accompanied with metabolic syndrome. Iran Red Crescent Med J. 2014;16(8):e12106. doi: 10.5812/ircmj.12106
  23. Kobayashi N, Hata N, Kume N, et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 as an early biomarker for ST elevation myocardial infarction: time-dependent comparison with other biomarkers: time-dependent comparison with other biomarkers. Circ J. 2011;75(6):1433-9. doi: 10.1253/circj. cj-10-0913
  24. Hussein RA, Abdul-Rasheed OF, Basheer M. Evaluation of soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) and sLOX-1/oxidized LDL ratio as novel biomarkers of acute coronary syndrome. Acta Biochim Pol. 2022;69(2):309-14. doi: 10.18388/abp.2020_5735
  25. Zhao ZW, Xu YW, Li SM, et al. Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention. Dis Markers. 2019;2019:4925767. doi: 10.1155/2019/4925767
  26. Besli F, Gullulu S, Sag S, et al. The relationship between serum lectin-like oxidized LDL receptor-1 levels and systolic heart failure. Acta Cardiol. 2016;71(2):185-90. doi: 10.2143/AC.71.2.3141848
  27. Stankova TR, Delcheva GT, Maneva AI, et al. Serum Levels of Carbamylated LDL, Nitrotyrosine and Soluble Lectin-like Oxidized Low-density Lipoprotein Receptor-1 in Poorly Controlled Type 2 Diabetes Mellitus. Folia Med (Plovdiv). 2019;61(3):419-25. doi: 10.3897/folmed.61.e39343
  28. Lee AS, Wang YC, Chang SS, et al. Detection of a High Ratio of Soluble to Membrane-Bound LOX-1 in Aspirated Coronary Thrombi from Patients With ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc. 2020;9(2):e014008. doi: 10.1161/JAHA.119.014008
  29. Li D, Li B, Yang L, et al. Human cytomegalovirus infection is correlated with atherosclerotic plaque vulnerability in carotid artery. J Gene Med. 2020;22(10):e3236. doi: 10.1002/jgm.3236
  30. Dogan I, Dogan T, Yetim M, et al. Relation of Serum ADMA, Apelin-13 and LOX-1 Levels with Inflammatory and Echocardiographic Parameters in Hemodialysis Patients. Ther Apher Dial. 2018;22(2):109-17. doi: 10.1111/1744-9987.12613
  31. Taskin HE, Kocael A, Kocael P, et al. Original contribution: sleeve gastrectomy reduces soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) levels in patients with morbid obesity. Surg Endosc. 2022;36(4):2643-52. doi: 10.1007/s00464-021-08989-8
  32. Vavere AL, Sinsakul M, Ongstad EL, et al. Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results. J Am Heart Assoc. 2023;12(3):e027540. doi: 10.1161/JAHA.122.027540
  33. Sui D, Yu H. Protective roles of apremilast via Sirtuin 1 in atherosclerosis. Bioengineered. 2022;13(5):13872-81. doi: 10.1080/21655979.2022.2085390
  34. Yang T, Minami M, Yoshida K, et al. Niclosamide downregulates LOX-1 expression in mouse vascular smooth muscle cells and changes the composition of atherosclerotic plaques in ApoE-/- mice. Heart Vessels. 2022;37(3):517-27. doi: 10.1007/s00380-021-01983-z
  35. Liu H, Xu S, Li G, et al. Sarpogrelate and rosuvastatin synergistically ameliorate aortic damage induced by hyperlipidemia in apolipoprotein E-deficient mice. Exp Ther Med. 2020;20(6):170. doi: 10.3892/etm.2020.9300
  36. Zhou S, Li Z, Liu P, et al. Donepezil Prevents ox-LDL-Induced Attachment of THP-1 Monocytes to Human Aortic Endothelial Cells (HAECs). Chem Res Toxicol. 2020;33(4):975-81. doi: 10.1021/acs.chemrestox.9b00509
  37. Togami K, Zhan X, Ishizawa K, et al. Development of LOX-1 Antibody Modified Immuno-liposomes as Drug Carriers to Macrophages in Atherosclerotic Lesions. Pharmazie. 2023;78(8):113-6. doi: 10.1691/ph.2023.3004
  38. Wang Z, Chen X, Liu J, et al. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPARγ pathway. Autoimmunity. 2022;55(4):223-32. doi: 10.1080/08916934.2022.2051142
  39. Zhang L, Cheng L, Wang Q, et al. Atorvastatin protects cardiomyocytes from oxidative stress by inhibiting LOX-1 expression and cardiomyocyte apoptosis. Acta Biochim Biophys Sin (Shanghai). 2015;47(3):174-82. doi: 10.1093/abbs/gmu131
  40. Biocca S, Iacovelli F, Matarazzo S, et al. Molecular mechanism of statin-mediated LOX-1 inhibition. Cell Cycle. 2015;14(10):1583-95. doi: 10.1080/15384101.2015.1026486
  41. Xiong Q, Wang Z, Yu Y, et al. Hydrogen sulfide stabilizes atherosclerotic plaques in apolipoprotein E knockout mice. Pharmacol Res. 2019;144:90-8. doi: 10.1016/j.phrs.2019.04.006
  42. Yu Z, Peng Q, Li S, et al. Myriocin and d-PDMP ameliorate atherosclerosis in ApoE-/- mice via reducing lipid uptake and vascular inflammation. Clin Sci (Lond). 2020;134(5):439-58. doi: 10.1042/CS20191028
  43. Yan L, Jia Q, Cao H, et al. Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice. Exp Ther Med. 2021;21(1):25. doi: 10.3892/etm.2020.9457
  44. Chiu TH, Ku CW, Ho TJ, et al. Schisanhenol ameliorates oxLDL-caused endothelial dysfunction by inhibiting LOX-1 signaling. Environ Toxicol. 2023;38(7):1589-96. doi: 10.1002/tox.23788
  45. Lee HS, Lee MJ, Kim H, et al. Curcumin inhibits TNF-alpha-induced lectin-like oxidised LDL receptor-1 (LOX-1) expression and suppresses the inflammatory response in human umbilical vein endothelial cells (HUVECs) by an antioxidant mechanism. J Enzyme Inhib Med Chem. 2010;25(5):720-9. doi: 10.3109/14756360903555274
  46. Luo R, Zhao L, Li S, et al. Curcumin Alleviates Palmitic Acid-Induced LOX-1 Upregulation by Suppressing Endoplasmic Reticulum Stress in HUVECs. Biomed Res Int. 2021;2021:9983725. doi: 10.1155/2021/9983725
  47. Xu S, Liu Z, Huang Y, et al. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-kappaB activation. Transl Res. 2012;160:114-24. doi: 10.1016/j.trsl.2012.01.008
  48. Wen J, Chang Y, Huo S, et al. Tanshinone IIA attenuates atherosclerosis via inhibiting NLRP3 inflammasome activation. Aging. 2020;13:910-32. doi: 10.18632/aging.202202
  49. Feng Z, Yang X, Zhang L, et al. Ginkgolide B ameliorates oxidized low-density lipoprotein-induced endothelial dysfunction via modulating Lectin-like ox-LDL-receptor-1 and NADPH oxidase 4 expression and inflammatory cascades. Phytother Res. 2018;32(12):2417-27. doi: 10.1002/ptr.6177
  50. Wang G, Liu Z, Li M, et al. Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK-9 Expression and Functionality. Biomed Res Int. 2019;2019:7284767. doi: 10.1155/2019/7284767
  51. Xu Q, Li YC, Du C, et al. Effects of Apigenin on the Expression of LOX-1, Bcl-2, and Bax in Hyperlipidemia Rats. Chem Biodivers. 2021;18(8):e2100049. doi: 10.1002/cbdv.202100049
  52. Bai X, Wang S, Shu L, et al. Hawthorn leaf flavonoids alleviate the deterioration of atherosclerosis by inhibiting SCAP-SREBP2-LDLR pathway through sPLA2-IIA signaling in macrophages in mice. J Ethnopharmacol. 2024;327:118006. doi: 10.1016/j.jep.2024.118006
  53. Ding Y, Feng Y, Zhu W, et al. [Gly14]-Humanin Prevents Lipid Deposition and Endothelial Cell Apoptosis in a Lectin-like Oxidized Low-density Lipoprotein Receptor-1-Dependent Manner. Lipids. 2019;54(11-12):697-705. doi: 10.1002/lipd.12195
  54. Yu J, Zhou L, Song H, et al. (-)-Epicatechin gallate blocked cellular foam formation in atherosclerosis by modulating CD36 expression in vitro and in vivo. Food Funct. 2023;14(5):2444-58. doi: 10.1039/d2fo03218j
  55. Li Q, Liu X, Zhang X, et al. Terpene Lactucopicrin Limits Macrophage Foam Cell Formation by a Reduction of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Lipid Rafts. Mol Nutr Food Res. 2022;66(4):e2100905. doi: 10.1002/mnfr.202100905
  56. Im YS, Gwon MH, Yun JM. Protective effects of phenethyl isothiocyanate on foam cell formation by combined treatment of oxidized low-density lipoprotein and lipopolysaccharide in THP-1 macrophage. Food Sci Nutr. 2021;9(6):3269-79. doi: 10.1002/fsn3.2293
  57. Pengnet S, Prommaouan S, Sumarithum P, et al. Naringin Reverses High-Cholesterol Diet-Induced Vascular Dysfunction and Oxidative Stress in Rats via Regulating LOX-1 and NADPH Oxidase Subunit Expression. Biomed Res Int. 2019;2019:3708497. doi: 10.1155/2019/3708497
  58. Manogaran M, Vuanghao L, Mohamed R. Gynura procumbens ethanol extract and its fractions inhibit macrophage derived foam cell formation. J Ethnopharmacol. 2020;249:112410. doi: 10.1016/j.jep.2019.112410

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. LOX-1 signalling pathways

Download (433KB)
Indexing metadata

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».